To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Valnoctamide
Valnoctamide (INN, USAN) has been used in France as an sedative-hypnotic since 1964.[2] It is a structural isomer of valpromide, a valproic acid prodrug; unlike valpromide, however, valnoctamide is not transformed into its homologous acid, valnoctic acid, in vivo.[3] Additional recommended knowledge
IndicationsIn addition to being a sedative, valnoctamide has been investigated for use in epilepsy since 1969[4] and was still being investigated in 2000[5] and 2003. It was studied for neuropathic pain in 2005 by Winkler et al, with good results: it had minimal effects on motor coordination and alertness at effective doses, and appeared to be equally effective as gabapentin.[6] RH Belmaker, Yuly Bersudsky and Alex Mishory started a clinical trial of valnoctamide for prophylaxis of mania in lieu of the much more teratogenic valproic acid or its salts.[7] Side effectsThe side effects of valnoctamide are mostly minor and include somnolence[8] and the slight motor impairments mentioned above. InteractionsValnoctamide is known to increase through inhibition of epoxide hydrolase the serum levels of carbamazepine-10,11-epoxide, the active metabolite of carbamazepine, sometimes to toxic levels.[9] ChemistryValnoctamide is a racemic compound with four stereoisomers, all of which were shown to be more effective than valproic acid in animal models of epilepsy and one of which ((2S,3S)-valnoctamide) was considered to be a good candidate by Isoherranen, et al for an anticonvulsant in August of 2003.[10] Notes and references
Categories: Anticonvulsants | Anxiolytics |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Valnoctamide". A list of authors is available in Wikipedia. |
- Chlorophyll
- Dysphagia
- Spinothalamic_tract
- Actin-binding_protein
- Evotec and Sartorius partner with start-up Curexsys on iPSC-based exosome approach - Exosomes are a promising novel approach for innovative regenerative therapies, as therapeutics in age-related conditions, but also for diagnostic purposes